# Starna Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/starna-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Suzhou, China
- Website: www.starnatx.com
- Total disclosed funding: $114M
- Latest round: Series B (May 11, 2026)
- Investors on record: 7

## About

Based in Suzhou, China and founded in 2021, Starna Therapeutics (Suzhou) Co., Ltd., trading as Starna Therapeutics, specializes in RNA-based drug development technologies and therapies. Its core team consists of professionals from established pharmaceutical companies, universities, and research institutions, with experience in nucleic acid drug discovery, delivery technologies, and formulation development. In May 2026, it raised approximately USD 40 million in series B+ funding from GL Ventures, LYFE Capital, Lilly Asia Ventures, Sherpa Healthcare Partners, Source Code Capital, and Primavera Capital Group.
Starna Therapeutics develops RNA-based therapeutics and drug delivery solutions, built on mRNA technology platforms and lipid nanoparticle (LNP) delivery systems, with capabilities spanning molecule discovery, formulation development, and preclinical research. The company maintains an extensive library of lipid materials and delivery candidates, enabling targeted delivery across multiple organs and tissues, and supports diverse dosage forms including injectable solutions, lyophilized formulations, and inhalable therapies, while advancing a pipeline of mRNA vaccines and therapeutic candidates addressing infectious diseases and other clinical indications.
The company generates revenue primarily through the development of RNA-based drug candidates and related technologies, as well as potential collaboration, licensing, and commercialization of its therapeutic pipeline and delivery platforms.
The company will use the series B+ funding in May 2026 to accelerate the clinical development of multiple in vivo CAR-T pipelines, advance the construction of extrahepatic delivery platforms for the lungs, intestines, and nervous system, and consolidate and strengthen its innovative R&D layout in the field of mRNA therapy.

## Funding rounds

- Series B, May 11, 2026, $40M — Lilly Asia Ventures, Primavera Capital Group, Source Code Capital, LYFE Capital, Sherpa Healthcare Partners, GL Ventures
- Series B, Oct 14, 2025, $42M — Lilly Asia Ventures, Primavera Capital Group, Source Code Capital, LYFE Capital, Sherpa Healthcare Partners, GL Ventures
- Series A, May 16, 2022, $22M — Hony Capital, Primavera Capital Group, Source Code Capital, LYFE Capital, Sherpa Healthcare Partners, GL Ventures
- Angel, Dec 13, 2021, $10M — Sherpa Healthcare Partners, GL Ventures

## Investors

- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Angel, Series A, Series B
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Angel, Series A, Series B
- Hony Capital (https://capitalatlas.ai/funds/hony-capital) — Series A
- Primavera Capital Group (https://capitalatlas.ai/funds/primavera-capital-group) — Series A, Series B
- Source Code Capital (https://capitalatlas.ai/funds/source-code-capital) — Series A, Series B
- LYFE Capital — Series A, Series B
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B